Moreover, we observe that the progressive alterations in the metabolic pathways, such as AKT/mTOR, insulin signaling, glycolysis, and de novo lipogenesis, involved in the NAFLD development at 12 and 24 weeks (Supplementary Figures S7 and S8). Here, AKT1 is linked to metabolic dysfunction-associated steatotic liver disease.